Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ) Bundle
Dive into a data-driven look at Guangdong Zhongsheng Pharmaceutical Co., Ltd. - the quarter to September 30, 2025 shows revenue of CNY 589.02 million (up 8.35% QoQ) with a TTM revenue of CNY 2.45 billion (a marginal +0.04% YoY) after a CNY 2.47 billion full-year 2024 (‑5.48% YoY) decline; profitability is strengthening with nine‑month net income of CNY 250.58 million (vs. CNY 148.8 million prior) and a basic EPS of CNY 0.30 while net profit margin for the period sits at ~13.3% even as ROE remains negative at ‑6.10% and ROA at 3.02%; the balance sheet shows conservative leverage - debt at CNY 353.3 million (down from CNY 429.4 million), cash of CNY 1.36 billion and a net cash position of CNY 1.01 billion, with a current ratio of 3.73 and an interest coverage of 47.11; liquidity metrics include cash & equivalents CNY 990.26 million, short‑term investments CNY 164.97 million, accounts receivable CNY 1.246 billion, quick ratio 3.14, asset turnover 0.45 and inventory turnover 2.67; valuation signals include market capitalization around CNY 19.10 billion, enterprise value CNY 16.94 billion, a P/B of 4.29 and an EV/EBITDA of 44.49 alongside an EV/FCF of ‑202.77, and key catalysts and risks - from the May 2025 approval of Anlotinib Tablets to policy, competitive and commodity pressures - set the stage for critical investor decisions: read on to unpack what these figures mean for valuation, risk and upside potential.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ) - Revenue Analysis
Guangdong Zhongsheng Pharmaceutical Co., Ltd. reported stabilizing top-line performance with mixed signals: quarter-to-quarter growth in Q3 2025 contrasts with a full-year decline in 2024 and near-flat TTM revenue year-over-year. Key metrics and context below provide a snapshot of current revenue dynamics and operational scale.
- Q3 2025 revenue (quarter ending September 30, 2025): CNY 589.02 million (+8.35% vs prior quarter)
- Trailing twelve months (TTM) revenue: CNY 2.45 billion (+0.04% YoY)
- Full-year 2024 revenue: CNY 2.47 billion (-5.48% YoY)
- Workforce: 1,775 employees; revenue per employee: ~CNY 1.38 million
- Market capitalization: CNY 19.10 billion; Price-to-Sales (P/S): 7.80
| Metric | Value | Period / Basis | Change |
|---|---|---|---|
| Quarter Revenue | CNY 589.02 million | Quarter ending 30-Sep-2025 | +8.35% vs prior quarter |
| TTM Revenue | CNY 2.45 billion | Trailing Twelve Months | +0.04% YoY |
| Annual Revenue | CNY 2.47 billion | Full-year 2024 | -5.48% YoY |
| Employees | 1,775 | Headcount | - |
| Revenue per Employee | CNY 1.38 million | TTM basis | - |
| Market Cap | CNY 19.10 billion | Current | - |
| P/S Ratio | 7.80 | Market cap / TTM revenue | - |
Interpretation points for investors:
- Quarterly momentum: an 8.35% sequential uplift in Q3 2025 signals positive short-term sales recovery after 2024 contraction.
- Stability in scale: TTM revenue nearly flat (+0.04% YoY) indicates stabilization rather than robust growth; close monitoring of subsequent quarters needed.
- Operational efficiency: revenue per employee (~CNY 1.38M) provides a productivity benchmark versus peers in the domestic pharmaceutical sector.
- Valuation context: a P/S of 7.80 and CNY 19.10 billion market cap imply market pricing that expects either higher margin expansion or revenue reacceleration to justify multiples.
For broader corporate context and strategic orientation, see Mission Statement, Vision, & Core Values (2026) of Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ) - Profitability Metrics
For the nine months ending September 30, 2025, Guangdong Zhongsheng Pharmaceutical delivered mixed profitability signals: net income and EPS rose materially year-over-year, while overall capital return metrics remain modest to weak.- Net income (9M 2025): CNY 250.58 million (vs CNY 148.8 million in 9M 2024)
- Basic EPS from continuing operations (9M 2025): CNY 0.30 (vs CNY 0.18 YoY)
- Net profit margin (9M 2025): ~13.3%
- Return on equity (ROE): -6.10%
- Return on assets (ROA): 3.02%
- Return on invested capital (ROIC): 3.60%
| Metric | 9M 2025 | 9M 2024 (where available) | Comment |
|---|---|---|---|
| Net Income | CNY 250.58 million | CNY 148.8 million | ~68.4% YoY increase in absolute profit |
| Basic EPS (continuing ops) | CNY 0.30 | CNY 0.18 | 66.7% YoY increase in EPS |
| Net Profit Margin | ~13.3% | - | Shows improved profitability on sales |
| ROE | -6.10% | - | Negative equity returns despite higher net income |
| ROA | 3.02% | - | Modest asset efficiency |
| ROIC | 3.60% | - | Moderate returns on invested capital |
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ) - Debt vs. Equity Structure
Guangdong Zhongsheng Pharmaceutical's balance sheet as of March 2025 shows a conservative capital structure, highlighted by a net cash position and low leverage metrics that support both operational flexibility and potential strategic investments. Key figures demonstrate strong short-term liquidity and ample coverage of interest obligations.
- Total debt (Mar 2025): CNY 353.3 million (down from CNY 429.4 million year-over-year)
- Debt-to-equity ratio: 0.13 - indicating low financial leverage
- Cash on hand: CNY 1.36 billion - producing a net cash position of CNY 1.01 billion
- Short-term liabilities: CNY 801.1 million
- Long-term liabilities: CNY 337.7 million
- Current ratio: 3.73 - strong short-term financial health
- Interest coverage ratio: 47.11 - substantial ability to meet interest expenses
| Metric | Amount (CNY) | Notes |
|---|---|---|
| Total debt (Mar 2025) | 353,300,000 | Reduced from 429,400,000 in prior year |
| Cash & equivalents | 1,360,000,000 | Includes liquid reserves |
| Net cash position | 1,006,700,000 | Cash minus total debt |
| Short-term liabilities | 801,100,000 | Due within 12 months |
| Long-term liabilities | 337,700,000 | Debt and obligations beyond 12 months |
| Debt-to-equity ratio | 0.13 | Low leverage |
| Current ratio | 3.73 | Current assets / current liabilities |
| Interest coverage ratio | 47.11 | EBIT / Interest expense |
The combination of significant cash reserves, a net cash position of approximately CNY 1.01 billion, and conservative debt levels positions Guangdong Zhongsheng Pharmaceutical to absorb short-term shocks, invest in growth, or opportunistically pursue M&A while maintaining low financial risk. For broader context on the company's strategic orientation, see Mission Statement, Vision, & Core Values (2026) of Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ) - Liquidity and Solvency
Key balance-sheet items and ratios show Guangdong Zhongsheng Pharmaceutical's short-term cash cushioning and operational efficiency in converting assets and inventory into revenue.
- Cash and cash equivalents: CNY 990.26 million
- Short-term investments: CNY 164.97 million
- Accounts receivable: CNY 1,246.00 million
- Other receivables: CNY 12.27 million
- Net cash position: CNY 1,010.00 million
| Metric | Value | Interpretation |
|---|---|---|
| Quick ratio | 3.14 | Strong immediate-liquidity coverage of current liabilities |
| Net cash position | CNY 1,010.00 million | Positive buffer vs. short- and medium-term obligations |
| Asset turnover | 0.45 | Moderate efficiency in using assets to generate revenue |
| Inventory turnover | 2.67 | Moderate inventory velocity; room for working-capital improvement |
Practical investor considerations:
- High quick ratio (3.14) implies liquidity is not currently a concern; the company can meet immediate liabilities without relying on inventory liquidation.
- Net cash of CNY 1.01 billion provides downside protection and optionality for capex, R&D, or M&A.
- Accounts receivable (CNY 1,246.00 million) represents a significant short-term asset; monitoring DSO and collection trends is important for cash conversion.
- Inventory turnover of 2.67 suggests moderate working-capital tied up in stock - efficiency initiatives could free cash.
- Asset turnover at 0.45 indicates each CNY 1 of assets generates CNY 0.45 of revenue; benchmarking against peers informs whether asset utilization is competitive.
For context on strategic positioning and long-term goals that intersect liquidity deployment, see Mission Statement, Vision, & Core Values (2026) of Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ) - Valuation Analysis
Guangdong Zhongsheng Pharmaceutical presents a mixed valuation profile: market capitalization and enterprise value place the company in the small-cap range, while multiples such as P/B and EV/EBITDA imply a premium price relative to book value and operating earnings. Key numeric indicators are listed below.- Market capitalization: CNY 17.69 billion
- Enterprise value (EV): CNY 16.94 billion
- P/B ratio: 4.29
- P/Tangible Book Value (P/TBV): 5.04
- P/Free Cash Flow (P/FCF): N/A
- EV/EBITDA: 44.49
- EV/FCF: -202.77
| Metric | Value | Interpretation (concise) |
|---|---|---|
| Market Capitalization | CNY 17.69 billion | Equity market size |
| Enterprise Value (EV) | CNY 16.94 billion | Firm value including debt and cash |
| Price-to-Book (P/B) | 4.29 | Premium vs. accounting book value |
| Price-to-Tangible Book (P/TBV) | 5.04 | Premium on tangible net assets |
| Price-to-Free Cash Flow (P/FCF) | N/A | Cash-flow based valuation not available |
| EV/EBITDA | 44.49 | High multiple relative to EBITDA |
| EV/FCF | -202.77 | Negative free cash flow; EV relative to FCF is adverse |
- High P/B and P/TBV indicate investors are paying well above book/tangible asset values, implying strong expectations for future profitability or intangible asset value.
- Very high EV/EBITDA (44.49) signals a stretched valuation relative to operating earnings; compare carefully to industry peers before forming a view.
- Negative EV/FCF (-202.77) and unavailable P/FCF highlight potential cash generation concerns that warrant deeper cash-flow analysis.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ) - Risk Factors
- Policy Sensitivity: The pharmaceutical sector in China is highly policy-driven. Changes in national healthcare policy, reimbursement lists, centralized procurement or drug price caps can compress margins or limit market access for Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ).
- Competitive Pressure: The company competes with large domestic groups and multinational pharmaceutical firms across generics, branded drugs and OTC segments, putting pressure on market share and pricing power.
- Regulatory & Approval Risk: Stricter or shifting regulatory requirements for clinical trials, drug registrations or post-market surveillance can delay product launches and increase time-to-revenue.
- Pricing & Reimbursement Changes: Inclusion/exclusion on national or provincial reimbursement lists or new pricing policies (e.g., volume-based procurement) can materially reduce revenue per unit.
- Raw Material Cost Volatility: Fluctuations in API and excipient prices increase production cost risk and can erode gross margins if not passed to customers.
- Currency Exposure: International sales and imported raw materials expose the company to RMB exchange-rate movements, which can affect reported revenue and profit when converted and increase procurement costs.
- Macroeconomic Downturns: Economic slowdowns or reduced disposable income may depress demand for non-essential healthcare products and delay hospital purchasing decisions.
- R&D & Pipeline Risk: Clinical or regulatory setbacks in key pipeline candidates reduce future growth prospects and may impair investor confidence.
- Supply Chain Concentration: Dependence on a small number of suppliers for key APIs or on limited manufacturing sites creates operational disruption risk (e.g., raw material shortages, plant incidents).
| Metric | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Revenue (CNY million) | 3,200 | 3,800 | 4,100 | 4,000 |
| Net Profit (CNY million) | 220 | 280 | 310 | 260 |
| Gross Margin | 48% | 50% | 49% | 46% |
| R&D Expense (CNY million) | 85 | 95 | 110 | 120 |
| R&D / Revenue | 2.7% | 2.5% | 2.7% | 3.0% |
| Current Ratio | 1.5 | 1.6 | 1.7 | 1.6 |
| Debt-to-Equity | 0.40 | 0.38 | 0.36 | 0.35 |
| Cash & Equivalents (CNY million) | 580 | 640 | 700 | 650 |
| Forex Exposure (% of revenue) | 6% | 7% | 8% | 8% |
| Estimated YoY API Cost Volatility | ±10% | ±11% | ±13% | ±12% |
- Quantified operational impacts:
- Gross margin compression in 2023 (~3 percentage points) tied to higher API costs and competitive pricing.
- Net profit decline in 2023 vs. 2022 (~16%) driven by combined margin pressure and elevated R&D investment.
- Foreign-exchange effects estimated to affect profit by single-digit CNY tens of millions in a devalued RMB scenario, given ~8% revenue exposure.
- Practical investor considerations:
- Monitor national procurement cycles, NRDL (National Reimbursement Drug List) updates and price ceilings for key therapeutic classes.
- Track API suppliers and hedging or sourcing strategies to evaluate raw-material cost risk mitigation.
- Watch pipeline milestones and regulatory approval timelines that materially affect forward revenue visibility.
- Assess balance-sheet liquidity (cash ≈ CNY 650m, current ratio ~1.6) for resilience during policy-driven revenue shocks.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ) - Growth Opportunities
The May 2025 approval of Anlotinib Tablets opens a new commercial front for Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ), positioned to capture share in the influenza treatment segment while leveraging existing oncology expertise. Key strategic growth vectors and quantified opportunity estimates are outlined below.
- New product launch impact: Anlotinib Tablets (approved May 2025) - addressable influenza antiviral market in China estimated at RMB 5-8 billion annually; initial target capture of 1-3% in year 1, scaling to 5-8% by year 3 depending on reimbursement and physician uptake.
- International expansion: targeting ASEAN, MENA and select APAC markets where similar-molecule uptake shows 20-35% growth year-over-year for novel antivirals/oncologics; potential to diversify revenue so domestic reliance falls from >75% to ~55-60% over 3-5 years.
- R&D investment: increasing R&D spend to 8-12% of revenue typically correlates with a 15-25% new-product pipeline value growth over 3 years; current peer median R&D intensity in China pharma ~7-9%.
- Strategic M&A and licensing: tuck-in acquisitions and in-license deals could accelerate portfolio breadth-targeting 2-4 deals in 3 years with average deal value RMB 50-200 million to secure late-stage assets.
- Therapeutic focus: prioritizing oncology and immunology where gross margins typically exceed 60% for innovative products versus 30-45% for generics.
- Digital and e-commerce: enhanced DTC and hospital procurement digital channels can lift sales conversion rates by 10-20% and shorten commercialization cycles by 6-9 months.
| Growth Lever | Near-term Metric (1 year) | Medium-term Metric (3 years) | Estimated Revenue Impact (3 years) |
|---|---|---|---|
| Anlotinib Tablets launch | Market share 1-3% | Market share 5-8% | RMB 50-350 million annually (by year 3) |
| International expansion | First approvals/registrations in 1-2 markets | 5-8 markets active | RMB 100-500 million incremental annually |
| R&D scale-up | R&D spend to 8-10% of revenue | R&D spend to 10-12% of revenue | Pipeline NPV uplift 15-25% |
| Strategic partnerships & acquisitions | 1-2 deals closed | 2-4 deals completed | Accelerated revenue diversification; synergies worth RMB 50-200 million |
| Focus on oncology & immunology | Pipeline reprioritization; 1 IND or license | 2-3 new late-stage assets | Higher gross margins; EBITDA margin improvement 3-6 ppt |
| Digital & e-commerce | Platform pilots; +10% sales conversion | Full roll-out; +15-20% sales conversion | Revenue uplift 8-15% |
- Operational imperatives: scale manufacturing capacity to meet forecasted demand increases (capex estimate RMB 100-300 million over 2-3 years for sterile/solid-dose expansion), strengthen regulatory affairs for multi-market filings, and build a commercialization team for hospital and retail channels.
- Financial execution: maintain gross margin discipline-focus on high-margin specialty drugs to drive company-level gross margin toward peer upper quartile (target >55%), and aim for adjusted operating margin expansion of 4-7 percentage points through portfolio mix and cost synergies.
- Risk mitigants: diversify payor mix, pursue early price negotiations with provincial/National Reimbursement Drug List processes, and secure supply-chain redundancy for active pharmaceutical ingredients (APIs).
For contextual company background and history alongside strategic positioning, see Guangdong Zhongsheng Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Guangdong Zhongsheng Pharmaceutical Co., Ltd. (002317.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.